Zacks Research Analysts Reduce Earnings Estimates for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Equities research analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for Agios Pharmaceuticals in a research report issued to clients and investors on Monday, September 9th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings per share of ($1.66) for the quarter, down from their previous forecast of ($1.58). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($1.62) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q2 2025 earnings at ($1.70) EPS, Q3 2025 earnings at ($1.74) EPS, FY2025 earnings at ($6.75) EPS, Q1 2026 earnings at ($1.56) EPS, Q2 2026 earnings at ($1.50) EPS and FY2026 earnings at ($5.62) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The business had revenue of $8.60 million for the quarter, compared to analyst estimates of $9.34 million. During the same quarter last year, the business earned ($1.51) EPS. Agios Pharmaceuticals’s revenue for the quarter was up 28.4% compared to the same quarter last year.

A number of other research analysts also recently commented on the stock. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $46.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Monday, June 17th. Royal Bank of Canada lifted their price target on Agios Pharmaceuticals from $53.00 to $55.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, August 5th. Finally, The Goldman Sachs Group lifted their target price on Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $51.33.

Agios Pharmaceuticals Trading Up 1.4 %

Agios Pharmaceuticals stock opened at $44.92 on Wednesday. The stock has a 50 day moving average of $45.37 and a 200-day moving average of $38.58. The stock has a market cap of $2.55 billion, a P/E ratio of -7.11 and a beta of 0.75. Agios Pharmaceuticals has a 52 week low of $19.80 and a 52 week high of $50.35.

Hedge Funds Weigh In On Agios Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. increased its stake in shares of Agios Pharmaceuticals by 1.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 456,394 shares of the biopharmaceutical company’s stock valued at $10,164,000 after purchasing an additional 4,699 shares during the period. BNP Paribas Financial Markets increased its position in Agios Pharmaceuticals by 111.5% in the 4th quarter. BNP Paribas Financial Markets now owns 125,309 shares of the biopharmaceutical company’s stock valued at $2,791,000 after acquiring an additional 66,070 shares during the period. Jump Financial LLC bought a new stake in Agios Pharmaceuticals during the 4th quarter valued at $362,000. Dimensional Fund Advisors LP boosted its position in Agios Pharmaceuticals by 5.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,596,764 shares of the biopharmaceutical company’s stock worth $57,832,000 after acquiring an additional 137,873 shares during the period. Finally, Norges Bank bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth $6,826,000.

Insider Activity

In other news, CEO Brian Goff sold 11,091 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the transaction, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at $3,368,358. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.93% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.